Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab.
Tomoyuki NagaokaHiroki OsumiTeruko UenoAkira OokiTakeru WakatsukiIzuma NakayamaMariko OguraDaisuke TakahariKeisho ChinKiyoshi MatsuedaKensei YamaguchiEiji ShinozakiPublished in: International journal of clinical oncology (2023)
MR predicts neither PFS nor OS; nevertheless, it may be useful when combined with the RECIST. The Ethics Committee of The Cancer Institute Hospital of JFCR approved this study in 2017 (No. 2017-GA-1123): retrospectively registered.
Keyphrases
- metastatic colorectal cancer
- papillary thyroid
- public health
- pet ct
- healthcare
- squamous cell
- big data
- magnetic resonance
- squamous cell carcinoma
- lymph node metastasis
- acute care
- computed tomography
- adverse drug
- emergency department
- phase ii study
- artificial intelligence
- drug administration
- newly diagnosed
- randomized controlled trial